



**NeoDynamics AB (publ)**  
**Q3 2023 Report**

1 January - 30 September 2023

# Focus on cash preservation

## Third Quarter 2023

- Revenues amounted to SEK 569 (222) thousand, of which SEK 0 (33) thousand net sales, i.e., sales of finished products.
- Net loss amounted to SEK -25,257 (-14,383) thousand.
- Loss per share amounted to SEK -0.09 (-0.12).
- Cash and cash equivalents amounted to SEK 4,609 (39,966 at year-end) thousand.

## Significant events during the quarter

- NeoDynamics AB (publ.) raised approximately SEK 58 million before the deduction of transaction costs, in a rights issue carried out during August. The rights issue was subscribed to approximately 80%, including guarantee commitments. Those subscribing by use of their exercise rights, corresponded to approximately 46.4%, with approximately 31.7% allocated to guarantors.
- In connection with the rights issue, NeoDynamics AB (publ.) also launched two warrant programmes, the T02 and T03. Details of both programmes can be found on the NeoDynamics website, [www.neodynamics.com](http://www.neodynamics.com) within the Investor section page.
- NeoDynamics AB (publ.) announced the initiation of their first NeoNavia® order from a prominent US university hospital specializing in the treatment of breast cancer. However modest in size, the order served as an important reference as the commercial rollout continues to garner interest and acceptance at both academic and community-based breast centers throughout the U.S. This milestone further demonstrates the commercial viability of the innovative pulse technology.

## Significant events after the end of the quarter

- NeoDynamics AB (publ.) announced the receipt of a new order for FlexiPulse needles from Western Rhineland-Palatinate Hospital in Germany. The hospital is among the top 100 rated and distinguished hospitals in Germany, and it serves as academic training hospital for the University of Mains. It has a large interdisciplinary sonography department performing all kinds of biopsies.
- NeoDynamics AB (publ.) announced cost reduction plan. The Board of Directors and Management Team decided to streamline the Company's operations to maximize its return on investment in key launch regions. As a result of these challenging but necessary changes to the organizational structure, dedicated team members will be impacted as the Company operates with a reduced headcount moving forward.
- In addition to the cost reduction plan, the Board of Directors are working to secure short-term financing by means of a bridge loan. The long-term solution that the board are exploring, is to secure sufficient capital to continue the commercialisation of NeoNavia® in Europe and the US, and includes, but is not limited to, early discussions about a potential sale of the company. There are no guaranties that the efforts to secure short or long-term financing will be successful.

## Cost reduction plan and streamlining of operations

During 2023, we have achieved several important milestones. However, we have faced delays in the product development. We chose, based on the feedback from our customers, to improve and finetune our needles, in particular, the CorePulse and VacuPulse. As a result, our sales development has been slower than expected as we have not had the full suite of needles.

Our financing has been linked closely to our expectations around the product availability, which we have tried to manage carefully. In general, the market has been difficult to operate in, especially when we consider how and when we raise capital for the company and the stage we are at.

Due to the combination of these factors, both internal and external, we have made the decision to reduce costs with due consideration to our current cash position. We truly believe we are close to a commercial breakthrough, which has been validated by positive customer feedback and recent orders. However, the fact that we did not secure as much financing in connection with the rights issue in August as intended, means that our current cash position is lower than anticipated. We therefore need to balance our cash, costs, and commercial activities in the short term.

We are having early discussions regarding a loan and potential sale of the company.

### Promising customer feedback

In general, we are getting very promising feedback from hospitals in both Europe and US.

Developments in Europe are quite satisfactory. Over the past months, we have held numerous workshops in Germany, Austria and the UK, and started a number of new pilots on various hospitals and clinics. Also, we have participated in the British Society of Breast Radiology (BSBR) meeting in Belfast, which has resulted in new orders and new pilot sites signed up. Likewise, we have successfully attended the DEGUM (German Society for Ultrasound in Medicine) at the Technical University of Munich with participation of doctors from Germany, Austria and Switzerland.

Some weeks ago, we were pleased to announce a new order for FlexiPulse needles from Western Rhineland-Palatinate Hospital which is among the top 100 rated and distinguished hospitals in Germany.



Our COMPULSE study in the UK, which is a comparative study using the Flexipulse needle to demonstrate product performance for ultrasound-guided biopsies of axillary lymph nodes in patients with breast cancer, is progressing according to plan. More than 148 patients (out of 400) have now been recruited (and biopsied). All COMPULSE study centers have confirmed that they intend to use our needles commercially, in parallel to participating in the study.

In the US, it is a waiting game. It takes time to get the final “go” in connection with the first order from a new customer. Thus, there is a lot of paperwork, compliance, administrative and legal tasks at the hospitals, that makes the route to success very cumbersome. This is not specific to NeoDynamics, but true for all companies in health care.

We are pleased, however, that we were able to announce our first order from a prominent University Hospital in the US in August. Also, we are currently in intense negotiations with Tier One Hospitals and are confident that we will be able to announce positive news in the near future.

### All three needles are ready

The fine-tuning of the CorePulse needle has been finalized, and the needle is now available for sale again. The same goes for the VacuPulse needle which has been improved both in vacuum strength and sharpness.

It means that our innovative biopsy system NeoNavia® is now fully functioning and available for sale with a full suite of improved needles; VacuPulse, CorePulse and FlexiPulse in all our targeted markets in Europe, while the FlexiPulse and VacuPulse needles are available for sale in the USA. The easiness of the “click and go” system as well as the simplicity of having one system for all three needles

is seen as one of the great features of NeoNavia by practitioners.

## Market update

NeoDynamics addresses an unmet need in the biopsy-based diagnosis of breast cancer, the most prevalent female cancer type, with an expected global market size of approx. USD 1.2bn by 2030 with a CAGR of approximately 7% according to MRFR 2023, which

confirms our growth expectations. The NeoNavia Pulse technology offers a highly precise needle delivery, with high-yielding tissue samples without the need for surgical procedures and improves the outcome for practitioners and quality of life for patients, which makes it a very strong product offering.

CEO Anna Eriksrud

# Financial overview

## Revenue and earnings

Revenues during the quarter amounted to SEK 569 (222) thousand, of which net sales were SEK 0 (33) thousand. The re-introduction of our CorePulse needle remains on-going, with centres in the UK and DACH region recently receiving their updated versions. We expect sales to start to materialize in the fourth quarter, as the US and European commercial efforts solidify.

Cost of goods were SEK 76 (21) thousand during the quarter, due to the phased roll out in the EU this year. Other external costs increased to SEK 10,334 (6,226) thousand, mainly reflecting higher costs for the establishment of NeoDynamics Inc. In addition, NeoDynamics has been working towards its MDR accreditation, which is required by law for all Medical Device companies in Europe. This has further contributed to the cost increase.

Personnel costs increased to SEK 7,991 (3,665) thousand during the quarter, an effect of several employees being onboarded in the US in combination with consultants being replaced with employees in Europe.

Operating loss amounted to SEK -22,118 (-14,441) thousand for the quarter whereas EBITDA, i.e., operating profit excluding depreciation, amounted to SEK -17,562 (-9,886) thousand for the quarter.

## Financial position

Cash and cash equivalents at the end of the period amounted to SEK 4,609 thousand (SEK 39,966 thousand at year-end). Financing, in the form of a Rights Issue, was carried out during August, raising SEK 58 million before transaction costs. The rights issue was subscribed to approximately 80%, including guarantee commitments. Those subscribing by use of their exercise rights, corresponded to approximately 46.4%, with approximately 31.7% allocated to guarantors.

The Board of Directors assesses that there is significant uncertainty about the company's liquidity.

Cash flow from operating activities before changes in working capital amounted to SEK -20,310, (-9,801) thousand and after changes in working capital to SEK -21,385 (-12,506) thousand. Receivables increased by SEK 33 thousand. The total cash flow amounted to SEK -3,058 (-12,830) thousand.

At period-end, the equity to assets ratio was 89 (94) percent and equity amounted to SEK 59,374 (110,699) thousand. The variance to last year, is due to the timing of the rights issue this year.

## The share

NeoDynamic's share was listed on Nasdaq First North Growth Market on May 2, 2022, with Redeye as Certified Adviser. The share's ticker is "NEOD" and the ISIN code is SE0011563410.

On September 30, 2022 the number of shares in NeoDynamics AB amounted to 120,501,184, up from 60,250,592, at year-end. A rights issue of 60,250,592 shares was completed during the second quarter of 2022, increasing the share capital by SEK 6,025,059 to SEK 12,050,119.

On September 30, 2023, the number of shares in the company was 698,940,514 and the last price paid in the period was SEK 0.0702. A rights issue of 578,439,330 shares was completed during the third quarter of 2023, with the share capital being maintained at SEK 12,050,119.

## Shareholders

On September 30, the company had a total of 4,023 shareholders, compared with 3,102 at year-end. The 10 largest shareholders at the end of the reporting period are listed in the table below.

<b>Name</b>	<b>Shareholding</b>	<b>Ownership</b>
Gryningskust Holding AB	238,065,602	34.06%
Rentability Sweden AB	28,781,308	4.12%
Avanza Pension	24,076,165	3.44%
John Fallström	21,632,676	3.10%
Huasheng Fang	13,631,896	1.95%
Humlan Fastighetsutveckling AB	12,176,010	1.74%
Formue Nord A/S	11,967,263	1.71%
Mikael Lönn	9,984,312	1.43%
Johan Waldhe	9,056,202	1.30%
Erik Åfors	8,080,527	1.16%
Others	321,488,553	45.99%

Financial calendar

Annual Accounts 2023	2024-02-16
Interim Report Jan-Mar (2024)	2024-05-07
Annual General Meeting	2024-05-22
Interim Report Jan-Jun (2024)	2024-08-20
Interim Report Jan-Sep (2024)	2024-11-19

## Risks and uncertainties

A number of risk factors could have a negative impact on NeoDynamics AB's operations. It is therefore important to consider any relevant risks in addition to the company's growth opportunities. As of recent, we see an added uncertainty in our surrounding world, both as a result of Russia's invasion of Ukraine and through a financial instability with rising inflation and general macroeconomic uncertainty. The company now stands ready to commercialize its first main product. The board and company management are assessing alternatives to secure financing of the commercialization and the company's long-term capital requirements on an ongoing basis. For a detailed outline of the risks attributable to the company and its shares, please refer to the prospectus published by the Board in March 2022.

## Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and in accordance with the Swedish Accounting Standards Board's general advice BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). For intangible assets, the activation model in the general council has been applied. The company's assets and liabilities are stated at cost and nominal value, unless otherwise stated.

## Review of the report

This interim report has not been reviewed by the company's auditor.

## Interim report submitted

The Board of Directors and the CEO hereby certify that this interim report provides a true and fair view of NeoDynamics' operations.

Lidingö on November 28, 2023

Anna Eriksrud  
CEO

Ingrid Salén  
Chairman of the Board

Carina Bolin  
Board member

Matthew E. Colpoys Jr  
Board member

Claes Pettersson  
Board member

NeoDynamics AB 559014-9117

## For further information, please contact

CEO Anna Eriksrud, phone +46 (0)708 444 966, e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

CFO Aaron Wong, phone +46 (0)79 010 1714, e-mail [aaron.wong@neodynamics.com](mailto:aaron.wong@neodynamics.com)

The company's Certified Adviser is Redeye AB.

## Consolidated accounts: Income statement

Amount in SEK thousands	Jul-Sep 2023	Jul-Sep 2022	Jan-Sep 2023	Jan-Sep 2022	Jan-Dec 2022
Net sales	0	33	117	135	135
Work performed by the Company for its own use and capitalized	233	73	430	214	214
Other operating income	336	116	682	423	553
	<b>569</b>	<b>222</b>	<b>1,229</b>	<b>772</b>	<b>902</b>
Cost of goods	-76	-21	-298	-195	-947
Other external costs	-10,334	-6,226	-34,910	-23,484	-38,239
Personnel costs	-7,911	-3,665	-22,921	-10,966	-16,321
Depreciation/amortization of tangible and intangible assets	-4,556	-4,555	-13,724	-13,585	-18,144
Other operating expenses	190	-196	-843	-314	-483
	<b>-22,687</b>	<b>-14,663</b>	<b>-72,696</b>	<b>-48,544</b>	<b>-74,134</b>
<b>OPERATING LOSS</b>	<b>-22,118</b>	<b>-14,441</b>	<b>-71,467</b>	<b>-47,772</b>	<b>-73,232</b>
Financial income	-3	2	108	77	103
Financial costs	-2,557	17	-3,272	-2	-3
	<b>-2,560</b>	<b>19</b>	<b>-3,164</b>	<b>75</b>	<b>100</b>
<b>LOSS AFTER FINANCIAL ITEMS</b>	<b>-24,678</b>	<b>-14,422</b>	<b>-74,631</b>	<b>-47,697</b>	<b>-73,132</b>
Tax	-78	39	556	39	-1,384
<b>NET LOSS</b>	<b>-24,756</b>	<b>-14,383</b>	<b>-74,075</b>	<b>-47,658</b>	<b>-74,516</b>
Number of shares at end of period	698,940,514	120,501,184	698,940,514	120,501,184	120,501,184
Average number of shares	275,543,213	120,501,184	172,749,780	93,687,189	102,627,636
<b>EARNINGS PER SHARE BEFORE DILUTION, SEK</b>	<b>-0.09</b>	<b>-0.12</b>	<b>-0.43</b>	<b>-0.51</b>	<b>-0.73</b>
(no dilution)					



## Consolidated accounts: Balance sheet

Amount in SEK thousands	30 Sep 2023	30 Sep 2022	31 Dec 2022
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangible assets	42,899	58,779	54,713
Tangible assets	1,037	1,789	1,575
Financial assets	134	138	138
Deferred tax	558	0	0
<b>Total non-current assets</b>	<b>44,628</b>	<b>60,706</b>	<b>56,426</b>
<b>Current Assets</b>			
Inventories	8,783	3,728	3,547
Accounts receivables	194	690	132
Other receivables	12,746	11,822	12,665
Prepaid expenses and accrued income	744	1,085	651
	<b>22,467</b>	<b>17,325</b>	<b>16,995</b>
<b>Cash and cash equivalents</b>	<b>4,609</b>	<b>39,966</b>	<b>20,067</b>
<b>Total current assets</b>	<b>27,076</b>	<b>57,291</b>	<b>37,062</b>
<b>TOTAL ASSETS</b>	<b>71,704</b>	<b>117,997</b>	<b>93,488</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital	12,057	12,050	12,050
Other contributed equity	294,827	303,060	303,725
Other equity incl. profit/loss for the year	-247,510	-204,411	-231,204
<b>Total equity</b>	<b>59,374</b>	<b>110,699</b>	<b>84,571</b>
<b>Provisions</b>			
Provisions for guarantee	500	240	500
<b>Long-term liabilities</b>			
Other long-term liabilities	0	665	0
<b>Current liabilities</b>			
Accounts payable	3,128	2,162	1,742
Current tax liability	1,490	0	1,448
Other liabilities	459	419	162
Accrued expenses	6,753	3,812	5,065
<b>Total current liabilities</b>	<b>11,830</b>	<b>6,393</b>	<b>8,417</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>71,704</b>	<b>117,997</b>	<b>93,488</b>

## Consolidated accounts: Cash flow statement

Amount in SEK thousands	Jul-Sep 2023	Jul-Sep 2022	Jan-Sep 2023	Jan-Sep 2022	Jan-Dec 2022
<b>Operating activities</b>					
Operating profit/loss	-22,118	-14,441	-71,467	-47,772	-73,232
Adjustments for items not included in cash flow	4,597	4,646	13,957	13,675	19,211
Interest received	2	-4	5	21	32
Interest paid	-2,791	-2	-3,291	-3	-3
Paid income tax	0	0	-8	0	0
<b>Cash provided by operating activities before changes in working capital</b>	<b>-20,310</b>	<b>-9,801</b>	<b>-60,804</b>	<b>-34,079</b>	<b>-53,992</b>
<i>Cash from changes in working capital</i>					
Increase (-) / decrease (+) in inventories	-594	-299	-5,747	-1,260	-1,593
Increase (-) / decrease (+) in account receivables	33	-70	-48	240	602
Increase (-) / decrease (+) in other receivables	-37	-1,439	95	-5,744	-6,072
Increase (+) / decrease (-) in account payables	-63	118	1,647	-2,715	-3,134
Increase (+) / decrease (-) in other operating liabilities	-414	-1,015	895	-1,149	-112
<b>Cash provided by operating activities</b>	<b>-21,385</b>	<b>-12,506</b>	<b>-63,962</b>	<b>-44,707</b>	<b>-64,301</b>
<b>Investing activities</b>					
Investment in intangible assets	-734	-146	-1,225	-819	-1,100
Investment in tangible assets	0	-115	0	-760	-760
Investment in financial assets	0	-14	0	-14	-14
<b>Cash used in investing activities</b>	<b>-734</b>	<b>-275</b>	<b>-1,225</b>	<b>-1,593</b>	<b>-1,874</b>
<b>Financing activities</b>					
Rights issue	57,844	0	57,844	69,288	69,288
Costs for rights issue	-8,083	-49	-8,083	-8,401	-8,382
Issuance of share options	0	0	0	338	338
Received loan	0	0	30,715	0	0
Amortization loan	-30,700	0	-30,700	0	0
<b>Cash used in financing activities</b>	<b>19,061</b>	<b>-49</b>	<b>49,776</b>	<b>61,225</b>	<b>61,244</b>
<b>Net change in cash and cash equivalents</b>	<b>-3,058</b>	<b>-12,830</b>	<b>-15,411</b>	<b>14,925</b>	<b>-4,931</b>
<b>Cash and cash equivalents, opening balance</b>	<b>7,754</b>	<b>52,782</b>	<b>20,067</b>	<b>24,960</b>	<b>24,960</b>
Foreign exchange differences in cash	-87	14	-47	81	38
<b>Cash and cash equivalents, ending balance</b>	<b>4,609</b>	<b>39,966</b>	<b>4,609</b>	<b>39,966</b>	<b>20,067</b>

## Condensed parent company income statement

Amount in SEK thousands	Jul-Sep 2023	Jul-Sep 2022	Jan-Sep 2023	Jan-Sep 2022	Jan-Dec 2022
Net sales	0	32	4,124	135	1,379
Work performed by the Company for its own use and capitalized	233	73	430	214	214
Other operating income	243	46	359	113	154
	<b>476</b>	<b>151</b>	<b>4,913</b>	<b>462</b>	<b>1,747</b>
Cost of goods	-131	-31	-1,272	-144	-895
Other external costs	-10,066	-8,497	-36,695	-31,069	-48,650
Personnel costs	-2,509	-1,693	-8,461	-5,643	-7,613
Depreciation/amortization of tangible and intangible assets	-4,556	-4,555	-13,722	-13,584	-18,144
Other operating expenses	-155	-36	-760	-190	-311
	<b>-17,417</b>	<b>-14,812</b>	<b>-60,910</b>	<b>-50,630</b>	<b>-75,613</b>
<b>OPERATING LOSS</b>	<b>-16,941</b>	<b>-14,661</b>	<b>-55,997</b>	<b>-50,168</b>	<b>-73,866</b>
Net financial items	-2,557	32	-3,268	53	-4,094
<b>LOSS AFTER FINANCIAL ITEMS</b>	<b>-19,498</b>	<b>-14,629</b>	<b>-59,265</b>	<b>-50,115</b>	<b>-77,960</b>
Tax	0	0	0	0	0
<b>NET LOSS</b>	<b>-19,498</b>	<b>-14,629</b>	<b>-59,265</b>	<b>-50,115</b>	<b>-77,960</b>

## Condensed parent company balance sheet

Amount in SEK thousands	30 Sep 2023	30 Sep 2022	31 Dec 2022
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangible assets	42,899	58,779	54,713
Tangible assets	1,033	1,789	1,575
Financial assets	12,743	2,398	372
<b>Total non-current assets</b>	<b>56,675</b>	<b>62,966</b>	<b>56,660</b>
<b>Current Assets</b>			
Inventories	7,219	3,728	3,406
Accounts receivables	194	690	132
Receivables from group companies	3,934	782	1,385
Other receivables and prepaid expenses	12,816	10,581	12,736
Cash and cash equivalents	2,887	37,607	16,534
<b>Total current assets</b>	<b>27,050</b>	<b>53,388</b>	<b>34,193</b>
<b>TOTAL ASSETS</b>	<b>83,725</b>	<b>116,354</b>	<b>90,853</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>	<b>70,845</b>	<b>108,325</b>	<b>81,164</b>
<b>Provisions</b>	<b>500</b>	<b>240</b>	<b>500</b>
<b>Other non-current liabilities</b>	<b>0</b>	<b>665</b>	<b>0</b>
<b>Current liabilities</b>			
Accounts payable	2,720	3,275	1,515
Liabilities to group companies	3,896	0	3,526
Other liabilities and accrued expenses	5,764	3,849	4,148
<b>Total current liabilities</b>	<b>12,380</b>	<b>7,124</b>	<b>9,189</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>83,725</b>	<b>116,354</b>	<b>90,853</b>

## Consolidated accounts: Key figures

	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
Net sales, SEK thousands	92	10	33	0	97	20	0
Operating loss, SEK thousands	-15,844	-17,487	-14,441	-25,459	-23,155	-26,193	-22,118
Operating margin %	neg	neg	neg	neg	neg	neg	neg
Balance sheet total, SEK thousands	91,468	133,007	117,997	93,488	77,760	78,683	71,704
Equity ratio %	89%	94%	94%	90%	79%	45%	83%
Cash, SEK thousands	10,785	52,782	39,966	20,067	5,366	7,754	4,609
Earnings/loss per share, SEK	-0.26	-0.16	-0.12	-0.22	-0.19	-0.22	-0.09
Equity per share, SEK	1.35	1.04	0.92	0.70	0.51	0.29	0.08

## Consolidated accounts: Statements of change in equity in summary

Amounts in SEK thousands	Jul-Sep		Jan-Sep		Jan-Dec
	2023	2022	2023	2022	2022
<b>Balance at the beginning of the period</b>	<b>35,404</b>	<b>125,190</b>	<b>84,571</b>	<b>97,476</b>	<b>97,476</b>
Warrant premium	0	0	0	0	338
Reclass warrant premium	0	0	0	0	327
Decrease share capital	0	0	0	0	0
New share issue	57,844	0	57,844	69,288	69,288
Costs for new share issue	-8,899	-49	-8,899	-8,402	-8,382
Translation difference	-219	-59	-67	-5	40
Profit(-loss) for the period	-24,756	-14,383	-74,075	-47,658	-74,516
<b>Balance at the end of the period</b>	<b>59,374</b>	<b>110,699</b>	<b>59,374</b>	<b>110,699</b>	<b>84,571</b>

## Definitions

<b>Earnings/Loss per share</b>	Earnings/loss for the period / average number of shares
<b>Equity / assets ratio</b>	Total equity / total assets
<b>Equity per share</b>	Equity at the end of the reporting period / average number of shares
<b>Operating margin</b>	Operating profit / net sales

## Warrant program – 2020/2023 and 2022/2025

The company has implemented two incentive programs aimed at senior executives in the company. In 2020, 1,021,900 warrants were issued with the right for holders to for each option subscribe for one (1) share with a subscription price of SEK 4.71 during the period August 1, 2023 – September 30, 2023. This programme has now expired and will not be exercised, due to the current share price.

In 2022, 2,640,000 warrants were issued with the right for holders to for each option subscribe for one (1) share with a subscription price of SEK 1.74 during the period February 17, 2025 – May 17, 2025.

The Board's ambition is to propose the issuance of warrants or equivalent up to a maximum total dilution of 5%.

There are no dilution effects during the period. The warrant terms are available on the company's website.

## NeoDynamics in brief

*NeoDynamics AB (publ) is a Swedish medical technology company dedicated to advancing the diagnosis and care of cancer. The company has an innovative biopsy system, NeoNavia®. The biopsy system is based on patented pulse technology, developed from research carried out at the Karolinska Institute in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for accurate diagnosis and individualized treatment. The launch of NeoNavia® has been initiated in the UK, Germany, Sweden and the U.S.*

### A growing breast biopsy market

At least 6 million breast biopsies are performed every year in order to detect suspected cancer. Every year, about 2.1 million women are diagnosed with breast cancer, a number that increases by 5 percent annually. The market for breast cancer diagnostics is growing and was estimated in 2025 to reach 830 million US dollars. The proportion of non-surgical biopsies is increasing at the expense of the surgical ones. Extended screening programs and new screening techniques enable more and more tumors to be detected earlier. New therapies are increasing the need for biopsies to confirm diagnoses but also to follow up on treatment results.

### NeoNavia® – a unique biopsy system

NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by pulses, enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for accurate diagnosis and individualized treatment. The product has CE approval since 2016 and received FDA clearance in 2022

### New innovative technology

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic driver that generates pulses is placed in a handheld instrument. Powered by the base unit, the driver accelerates the needle with great control even

over a short distance, enabling its distinct stepwise insertion without risking to destroy surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations as well as in dense tissue.

### Intellectual Property

The technology is protected in Europe's larger countries as well as in China and the USA. Patents for technology in the proprietary needle have been approved in Europe, the USA and China. The company's various patents run until 2034 and additional patent applications have been filed.

### Good results in clinical studies

The PULSE study (ClinicalTrials.gov ID: NCT03975855) shows that the system performs well when used in axillary lymph nodes. The patented pulse technology was considered to stabilize the target organ lymph node and improve needle control during insertion, and it was possible to obtain multiple samples with a single needle insertion.

### Tomorrow's breast cancer biopsy

NeoDynamics' vision is that our pulse technology will become the new standard for all ultrasound-guided breast cancer biopsies, and that precision and reliability will be improved, thereby helping to save lives and improve the quality of life of all women with breast cancer.

**“The NeoNavia® biopsy system can safely increase the precision of ultrasound-guided, technically difficult biopsies such as in the axillary lymph nodes.”**

Ref 1, Markets and Markets, September 2020 <https://www.marketsandmarkets.com/Market-Reports/biopsy-devices-breast-biopsy-market-189011805.html> Schässburger K, Paepke S. Po86. Novel pulse biopsy platform incorporating adaptive open-tip sampling needle increases sampling yield and needle control. European Journal of Surgical Oncology. 2021;47(5). doi:10.1016/j.ejso.2021.03.090.